Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
T. Vandemoortele, I. Nanni-Metellus, E. Kaspi, V. Secq, S. Laroumagne, P. Roll, E. Roca, H. Dutau, A. Robaglia, P. Astoul (Marseille, France). EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice. Eur Respir J 2013; 42: Suppl. 57, 5092

Member's Comments

No comment yet.

Related content which might interest you: A detailed immunohistochemical analysis of PI3K/AKT/MTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement: Analysis of two cases and literature review Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Validation of PNA-LNA PCR clamp assay for detection of EGFR exon 19 and 21 mutations in various types of clinical non-small cell lung cancer specimens Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 EGFR frequency and response to chemotherapy in a Brazilian NSCLC population Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Is residential radon associated with mutations in drivers genes in never smokers lung cancer cases? The case of EGFR and ALK Source: International Congress 2016 – Epidemiology and specific subgroups in lung cancer Year: 2016 Allele-specific real-time PCR detection of EGFR exon 19 and 21 mutations in various clinical non-small cell lung cancer specimens Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype Source: Eur Respir J 2014; 43: 872-883 Year: 2014 RT-PCR and IHC as the alternative methods for detection of ALK aberrations in NSCLC samples - The feasibility study Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015 Feasibility of bronchoscopy obtained tissue for tumor diagnosis and testing epidermal growth factor receptor (EGFR) mutational status Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases Year: 2013 Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Noninvasive detection of EGFR T790M mutation in gefitinib resistant non-small cell lung cancer using mutant-enriched PCR Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 EGFR mutations determine EGFR-MET crosstalk and MET inhibition in lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 The diagnosis and incidence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutation in lung adenocarcinoma Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 European mapping of EGFR mutation test and EGFR tyrosine kinase inhibitors availability in thoracic oncology Source: International Congress 2015 – Quality management in lung cancer Year: 2015